Table 2S

Comparison of BUN concentrations, urinary RPA-1 concentrations, and kidney histopathological severity in individual F344 rat following dietary exposure to melamine and cyanuric acid

| Concentration<br>of melamine<br>and cyanuric<br>acid in diet<br>(ppm) | 0   |   | 120                                       |   | 180  |   | 240  |  |
|---|---|---|---|---|--|---|--|--|
| Sex   | Males                                     | Females                                   | Males                                     | Females                                   | Males  | Females                                     | Males  | Females  |
| Rat ID  | 1, 2, 3, 4, 5, 6, 7, 8                    | 1, 2, 3, 4, 5, 6, 7, 8                    | 1, 2, 3, 4, 5, 6, 7,8                     | 1, 2, 3, 4, 5, 6, 7, 8                    | 1, 2, 3, 4, 5, 6, 7, 8                         | 1, 2, 3, 4, 5, 6, 7, 8                      | 1, 2, 3, 4, 5, 6, 7, 8                       | 1, 2, 3, 4, 5, 6, 7, 8                         |
| Dilatation,<br>Renal Tubule <sup>b</sup>                              | 0a, 0, 0, 0, 0, 0, 0, 0, 0                | 0, 0, 0, 0, 0, 0, 0                       | 0, 0, 0, 0, 0, 0, 0                       | 0, 0, 0, 0, 0, 0, 0                       | 3, 3, 1, 2, 0, 0, 1, 2                         | 0, 2, 2, 0, 0, 0, 0, 0                      | 4, 4, 4, 4, 4, 4, 4                          | 3, 4, 3, 4, 4, 4, 4, 4                         |
| Fibrosis <sup>b</sup>   | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 2, 0, 0, 0, 0, 0, 0                         | 0, 0, 0, 0, 0, 0, 0, 0                      | 0, 0, 0, 0, 2,4, 3, 4                        | 0, 0, 0, 0, 2, 2, 3, 3                         |
| Regeneration, renal tubule <sup>b</sup>                               | 1, 1, 1, 0, 1, 1, 1, 1                    | 0, 1, 1, 1, 0, 0, 0, 0                    | 1, 0, 1, 1, 1, 1, 1, 2                    | 1, 1, 0, 1, 0, 0, 0, 1                    | 4, 4, 2, 3, 1, 1, 2, 3                         | 2, 3, 3, 1, 2, 2, 1, 1                      | 4, 4, 4, 4, 4, 4, 4                          | 3, 4, 3, 4, 4, 4, 4, 4                         |
| Necrosis, Renal<br>Tubule,<br>Epithelium <sup>b</sup>                 | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 1, 0, 0, 0, 0, 1, 0                         | 0, 0, 0, 0, 0, 0, 0, 0                      | 2, 2, 2, 2, 2, 3, 2, 3                       | 1, 2, 2, 2, 2, 2, 2                            |
| Infiltration cellular, lymphocyte                                     | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 1, 0, 0, 1, 1, 0, 0, 0                         | 1, 0, 0, 0, 0, 1, 0, 0                      | 2, 0, 0, 0, 0, 2, 0, 2                       | 0, 0, 0, 0, 0, 1, 2, 2                         |
| Hyperplasia,<br>Pelvis,<br>Transitional<br>Epithelium <sup>b</sup>    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 2, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 0                    | 0, 0, 0, 0, 0, 0, 0, 3                         | 0, 0, 2, 0, 0, 0, 0, 0                      | 3, 2, 2, 3, 1, 1, 0, 1                       | 1, 3, 2, 1, 1, 2, 2, 3                         |
| Blood BUN<br>(mg/dl) <sup>b</sup>                                     | 13, 17, 23, 17, 17, 17, 17, 16, 17        | 17, 19, 15, 13, 17, 18, 15, 17            | 13, 13, 13, 12, 17, 17, 13, 16            | 11, 14, 16, 13, 21, 16, 15, 17            | 16, 18, 16, 15, 12,<br>16, 12, 14              | 11, 10, 10, 13, 16, 12, 17, 15              | 55, 92, 49, 51, 92,<br>176, 137, 110         | 42, 48, 21, 92, 61, 52, 84, 49                 |
| Urinary RPA-1<br>(µg/mg Cr) <sup>c</sup>                              | 1.9, 1.5, 1.9, 1.6,<br>2.5, 2.2, 1.7, 2.5 | 1.4, 1.3, 1.4, 1.7,<br>1.3, 1.4, 1.3, 2.1 | 2.5, 3.3, 7.5, 7.3,<br>2.5, 2.2, 4.6, 2.4 | 1.1, 1.2, 1.9, 3.1,<br>1.0, 1.3, 1.2, 1.4 | 20.1, 16.4, 8.9,<br>110, 8.1, 19, 9.9,<br>22.1 | 6.1, 23.2, 7.1, 3.0,<br>4.1, 10.3, 3.4, 5.8 | 7.8, 7.6, 9.9, 13.1,<br>18.5, 6.6, 14.2, 2.6 | 16.2, 5.8, 50.4, 17.3,<br>12.4, 10.6, 7.4, 3.9 |

<sup>&</sup>lt;sup>a</sup>Kidney lesion severity qualified as: 0 = not observed, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked.

<sup>&</sup>lt;sup>b</sup>Kidney histopathological changes and blood BUN levels were examined at the end of study.
<sup>c</sup>Urinary RPA-1 levels were analyzed for day 28 for control and low dose groups (120 ppm and 180 ppm). At the highest dose group (240 ppm), the levels of RPA-1 were analyzed for day 14.